KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Non-Current Liabilities (2016 - 2026)

Pacira BioSciences has reported Total Non-Current Liabilities over the past 17 years, most recently at $538.9 million for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities fell 30.07% year-over-year to $538.9 million; the TTM value through Mar 2026 reached $538.9 million, down 30.07%, while the annual FY2025 figure was $551.2 million, 27.31% down from the prior year.
  • Total Non-Current Liabilities for Q1 2026 was $538.9 million at Pacira BioSciences, down from $551.2 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $1.1 billion in Q1 2022 and troughed at $538.9 million in Q1 2026.
  • A 5-year average of $755.1 million and a median of $745.1 million in 2024 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 80.24% in 2022 and later crashed 33.91% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $878.1 million in 2022, then fell by 21.34% to $690.7 million in 2023, then grew by 9.8% to $758.4 million in 2024, then dropped by 27.31% to $551.2 million in 2025, then dropped by 2.25% to $538.9 million in 2026.
  • Business Quant data shows Total Non-Current Liabilities for PCRX at $538.9 million in Q1 2026, $551.2 million in Q4 2025, and $552.5 million in Q3 2025.